Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis

医学 杜瓦卢马布 内科学 养生 肺炎 子群分析 荟萃分析 肺癌 不利影响 肿瘤科 置信区间 危险系数 癌症 肺 彭布罗利珠单抗 免疫疗法
作者
Yu Wang,Tao Zhang,Yilin Huang,Wei Li,Jingjing Zhao,Yin Yang,Canjun Li,Lühua Wang,Nan Bi
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:112 (5): 1154-1164 被引量:101
标识
DOI:10.1016/j.ijrobp.2021.12.150
摘要

Consolidation durvalumab after chemoradiation therapy (CRT) has improved patient outcomes in stage III non-small cell lung cancer (NSCLC) since the practice-changing results of the PACIFIC trial, whereas real-world evidence regarding the PACIFIC regimen has not been systematically reviewed. This meta-analysis comprehensively investigated the real-world toxicity and efficacy of this regimen and identified differences between the real world and clinical trials.Real-world studies (RWSs) on patients with stage III NSCLC treated with durvalumab after CRT were identified in MEDLINE, EMBASE, PubMed, and Cochrane Library databases. We summarized the differences in demographic and therapeutic characteristics between RWSs and the PACIFIC trial. A meta-analysis of short-term efficacy and adverse event rates was performed. Subgroup analyses were conducted to identify potential influencing factors.Thirteen studies involving 1885 patients were included. More elderly and poor-performance-status patients, prolonged interval from CRT completion to durvalumab exceeding 42 days, median infusions of durvalumab <20 cycles, and sequential CRT were observed in the real world. The pooled 12-month overall survival (OS) and progression-free survival (PFS) rates were 90% (95% confidence interval [CI], 83%-98%) and 62% (95% CI, 56%-68%), respectively. Subgroup analysis determined that delay in durvalumab initiation beyond 42 days did not affect 12-month OS (P = .068) or PFS (P = .989). Pooled incidences of all-grade and grade ≥3 pneumonitis were 35% (95% CI, 22%-48%) and 6% (95% CI, 3%-8%), respectively. Higher all-grade pneumonitis rates were observed in the studies of patients with a median age of >65 years (P = .008) and from Asian regions (P = .017), whereas expanded access program-related studies reported significantly lower rates (P = .024).The safety and short-term efficacy of consolidation durvalumab in real-life use aligns with the PACIFIC trial. RWSs can be helpful for understanding the true efficacy and toxicity of consolidation durvalumab given the less-restrictive eligibility criteria.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
由哎完成签到,获得积分0
2秒前
2秒前
2秒前
2秒前
2秒前
郑睿涛发布了新的文献求助10
2秒前
小二郎的应助被111舒舒采纳,获得10
3秒前
4秒前
顾阿途完成签到 ,获得积分10
5秒前
wjwless完成签到,获得积分10
5秒前
6秒前
tlc_191026发布了新的文献求助30
6秒前
YCH发布了新的文献求助10
6秒前
6秒前
wjp发布了新的文献求助10
7秒前
zzzy完成签到 ,获得积分10
7秒前
无极微光的应助被1111111采纳,获得20
7秒前
123的应助被INFINITY采纳,获得10
8秒前
李健的小迷弟的应助被INFINITY采纳,获得10
8秒前
LuckyYu完成签到 ,获得积分20
8秒前
火山发布了新的文献求助10
8秒前
科研通AI6.4的应助被INFINITY采纳,获得10
8秒前
完美世界的应助被INFINITY采纳,获得10
8秒前
搜集达人的应助被INFINITY采纳,获得10
8秒前
溧谦发布了新的文献求助10
8秒前
chunyan_sysu发布了新的文献求助10
8秒前
赘婿的应助被INFINITY采纳,获得10
8秒前
斯文败类的应助被INFINITY采纳,获得10
8秒前
香蕉觅云的应助被INFINITY采纳,获得10
8秒前
FashionBoy的应助被INFINITY采纳,获得10
9秒前
隐形曼青的应助被INFINITY采纳,获得30
9秒前
俭朴大碗发布了新的文献求助10
10秒前
今后的应助被冲冲采纳,获得10
10秒前
10秒前
标致哑铃完成签到,获得积分10
11秒前
11秒前
renn发布了新的文献求助20
11秒前
12秒前
沐木发布了新的文献求助10
13秒前
水弘的应助被怕孤独的白容采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371